Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge?

JAMA Oncol. 2021 Oct 1;7(10):1449-1450. doi: 10.1001/jamaoncol.2021.2761.

Authors

Samer Al Hadidi^{1

2}, Sarvari Yellapragada³

Affiliations

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston.
² Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
³ Michael E. Debakey VA Medical Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

PMID: 34383000
DOI: 10.1001/jamaoncol.2021.2761

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Treatment Outcome

Substances

Dexamethasone